Skip to content
Danielle S. Wallace, M.D.

Danielle S. Wallace, M.D.

Cancer

Contact

Call Center (585) 276-3000

Locations

Wilmot Cancer Institute

601 Elmwood Ave
Rochester, NY 14642-0001

About Me

Professional Background

I am a clinician researcher dedicated to the care and treatment of patients with lymphoma. I was drawn to this area of oncology because of the immense amount of hope we can offer patients; many types of lymphoma are treated with the intent to cure, and we frequently have a variety of treatment choic...
I am a clinician researcher dedicated to the care and treatment of patients with lymphoma. I was drawn to this area of oncology because of the immense amount of hope we can offer patients; many types of lymphoma are treated with the intent to cure, and we frequently have a variety of treatment choices available, including clinical trials. While coming to an oncology office will always feel overwhelming at first, I strive to offer clear communication about a patient's disease and treatment so they feel comfortable and confident in our care plan. Oncology is a field with strong physician-patient relationships, and I value this opportunity to get to know all my patients well.

We have an incredible multidisciplinary team to support our patients at Wilmot, ranging from a large clinical trial office, to specialized nursing and advanced practice providers, to radiation oncologists, pathologists and dermatologists with expertise in lymphoma. We work together to assure that the entire patient experience is a positive one.

As a native of Upstate NY, I am proud to walk into Wilmot and know that we are providing our patients with world-class care, close to home.

Diseases I Treat:

Lymphoma, with a focus on nodal and cutaneous T-cell lymphomas
CAR T-cell and other cellular therapy

Certified Specialties

Internal Medicine - American Board of Internal Medicine

Faculty Appointments

Assistant Professor - Department of Medicine, Hematology/Oncology (SMD)

Credentials

Education

MD | SUNY Upstate Medical University. Medicine. 2016

BS | St. Bonaventure University. Biology. 2011

Awards

American Society of Hematology Medical Educators Institute. 2023

Segel-Halterman Award for Research in Hematology. 2022

Wilmot Cancer Institute Fellowship Award in Humanism. 2021

Arnold P. Gold Foundation Humanism and Excellence in Teaching Award. 2018

Alpha Omega Alpha Honor Society. 2015

Gold Humanism Honor Society. 2015

Publications

Journal Articles

ALK-rearranged CD30-positive poorly differentiated lung adenocarcinoma, mimicking anaplastic large-cell lymphoma.

George GV, Wallace DS, Wang Y, Carney J, Elsadawi M, Burack WR, Evans AG, Barr PM, Velez MJ, El Hussein S

Histopathology.. 2023 November 30 Epub 11/30/2023.

Response-Adapted, Time-Limited Venetoclax, Umbralisib and Ublituximab for Relapsed/Refractory Chronic Lymphocytic Leukemia.

Hill BT, Ma S, Zent CS, Baran AM, Wallace DS, Advani AS, Winter AM, Winter JN, Gordon LI, Karmali R, Liesveld JL, Mulford DA, Rowland C, Bui A, Sportelli P, Miskin HP, Weiss MS, Friedberg JW, Barr PM

Blood advances.. 2023 October 23 Epub 10/23/2023.

Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphoma.

Wallace DS, Rowland C, Hill BT, Baran AM, Casulo C, Reagan PM, Winter A, Karmali R, Winter JN, Gordon LI, Bui A, Sportelli P, Miskin HP, Weiss MS, Friedberg JW, Ma S, Barr PM

Leukemia & lymphoma.. 2023 June 21 :1-4. Epub 06/21/2023.

Rituximab induced cytokine release with high serum IP-10 (CXCL10) concentrations is associated with infusion reactions.

Moore JE, Bloom PC, Chu CC, Bruno JE, Herne CA, Baran AM, Quataert SA, Mosmann TR, Taylor RP, Wallace DS, Elliott MR, Barr PM, Zent CS

Leukemia research.. 2023 March 29129 :107072. Epub 03/29/2023.

Acalabrutinib and High-Frequency Low-Dose Subcutaneous Rituximab for Initial Therapy of Chronic Lymphocytic Leukemia.

Wallace DS, Zent CS, Baran AM, Reagan PM, Casulo C, Rice G, Friedberg JW, Barr PM

Blood advances.. 2023 January 23 Epub 01/23/2023.

Wallace, DS; Reagan PM.

Age is just a number: managing relapsed or refractory diffuse

Early Progressing Follicular Lymphoma.

Wallace D, Casulo C

Current oncology reports.. 2021 November 1923 (12):149. Epub 11/19/2021.

Novel Treatments for Mantle Cell Lymphoma: From Targeted Therapies to CAR T Cells.

Wallace D, Reagan PM

Drugs.. 2021 March 30 Epub 03/30/2021.

A Multicentered Academic Medical Center Experience of a Simulated Root Cause Analysis (RCA) for Hematology/Oncology Fellows.

Wallace D, Cochran D, Duff J, Close J, Murphy M, Baran A, Patel A

Journal of cancer education : the official journal of the American Association for Cancer Education.. 2020 October 14 Epub 10/14/2020.

Gin Would Be Better.

Wallace D

Journal of palliative medicine.. 2020 August 23 (8):1132. Epub 1900 01 01.

Additional B-cell malignancies in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL).

Meacham PJ, Williams AM, Strawderman M, Baran AM, Archibald WJ, Wallace DS, Tschernia NP, Burack WR, Barr PM, Zent CS

Leukemia & lymphoma.. 2020 March 16 :1-9. Epub 03/16/2020.